Presently, there is no targeted treatment available for human respiratory syncytial virus (hRSV) infection other than the supportive care to mitigate the signs of and symptoms. Antiviral drug development and RSV vaccine is expected to play a critical role in overall reduction of RSV infections globally. Continued effort in RSV research published in high profile scientific journals has invigorated efforts by larger and smaller pharmaceutical and biotechnology companies to develop antivirals and RSV vaccines. Preclinical development of vaccines is hindered by the lack of clinically relevant rodent models.
In summary, this article includes in-house as well as client-sponsored study data established over several years using SCID mouse models. These studies generated clinically pertinent information for proper screening of new vaccines and antivirals.